RxDoctor Payments Data

Onika Popo-James, DO

Family Medicine · Stockbridge, GANPI 1295972032

Payments from drug & device makers

$3,685in general payments, 2019–2025

Across 175 payments — averaging $21.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$528
  • Novo Nordisk$459
  • AstraZeneca$418
  • Lilly USA, LLC$381
  • Bayer$245
  • Amgen$220
  • plus $1K from 27 others

What the payments were for

  • Food & beverage$3,685100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,685 in reported general payments places this provider in the 80th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$24,547
Medicare patients
70
Services billed
1,155

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide36$48,229
OzempicSemaglutide32$40,581
JardianceEmpagliflozin27$36,562
FarxigaDapagliflozin Propanediol32$34,931
LinzessLinaclotide12$12,546
XareltoRivaroxaban11$5,677
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$2,878
Rosuvastatin Calcium93$1,064
Liothyronine Sodium25$602
Azelastine Hcl28$560
Fluticasone Propionate44$548
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst11$547
Losartan Potassium77$517
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen13$469
Montelukast Sodium34$398

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$381$48,22936 claims
Novo NordiskOzempic$459$40,58132 claims
Boehringer IngelheimJardiance$59$36,56227 claims
AstraZenecaFarxiga$418$34,93132 claims
AbbVieLinzess$528$12,54612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Stockbridge

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →